Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 9, 2026Journal of Clinical MedicineOpen Access

Preventing Hip (Proximal Femoral) Fractures: An Evidence-Based Review for Clinicians

View Full Paper
Ask AI
Bookmark
Share

Authors

TKToshiyuki KawaiYOYaichiro OkuzuYTYusuke Takaoka

Discussion

Loading...

Member takes

Overview

Evidence-based review highlights effective prevention strategies for hip fractures, addressing aging populations.

Key Points

  • This review aims to summarize contemporary evidence on the prevention and risk factors of proximal femoral fractures.
  • Reviewed PubMed-indexed studies on hip fracture prevention and outcomes.
  • Discussed non-pharmacologic (exercise, hazard modification) and pharmacologic interventions (bisphosphonates, denosumab).
  • Evaluated health-system interventions for primary and secondary prevention of fractures.
  • Long-term balance-challenging and resistance-based exercise significantly reduces falls.
  • Bisphosphonates and denosumab show strong evidence for reducing hip-fracture risk.
  • Integrated care approaches and adherence support are critical for effective fracture prevention.

Cite This Study

Kawai et al. (2026) studied this question.

synapsesocial.com/papers/6a782d7b2e1896536c8409eehttps://doi.org/10.3390/jcm15166148
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea2024 · 6 citations
  2. 2Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline2024 · 545 citations
  3. 3Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study2016 · 197 citations
  4. 4Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial2012 · 150 citations
  5. 5Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study2025 · 8 citations